Physician profile
Michael C Marte
NPI 1518058502
$5,262.59
in general payments reported to CMS, 2019-2025
52 companies · $1,392 in 2025
The $1,392 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $824 · 2020: $398 · 2021: $125 · 2022: $40.03 · 2023: $1,079 · 2024: $1,405 · 2025: $1,392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,776 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,776.28 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $479.79 | 2019-2025 | |
| Janssen Biotech, INC. | $472.92 | 2019-2025 | Erleada, Rybrevant, Darzalex |
| Pfizer INC. | $367.83 | 2019-2025 | |
| Daiichi Sankyo INC. | $293.15 | 2019-2025 | Enhertu, Datroway, Injectafer |
| Genentech USA, INC. | $244.12 | 2019-2025 | Tecentriq, Itovebi, Phesgo |
| Merck Sharp & Dohme LLC | $240.45 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Exelixis INC. | $236.43 | 2019-2025 | Cabometyx |
| Genzyme Corporation | $200.87 | 2019-2025 | |
| Pharmacosmos Therapeutics INC. | $194.89 | 2023-2025 | Monoferric, Cosela |
| Celgene Corporation | $183.77 | 2019-2025 | Reblozyl, Pomalyst |
| E.R. Squibb & Sons, L.L.C. | $171.44 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Amgen INC. | $158.23 | 2019-2023 | Lumakras, Nplate, Vectibix |
| Takeda Pharmaceuticals U.S.A., INC. | $152.46 | 2019-2025 | Ninlaro, Iclusig |
| Emd Serono, INC. | $145.54 | 2019-2024 | |
| Seagen INC. | $129.17 | 2019-2025 |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmaessentia USA Corporation | $128.46 | 2023-2025 | Besremi |
| Astellas Pharma US INC | $112.07 | 2019-2025 | Cresemba, Xtandi, Xospata |
| Gilead Sciences, INC. | $108.87 | 2023-2025 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $108.74 | 2019-2024 | Imfinzi |
| Puma Biotechnology, INC. | $97.42 | 2019-2023 | |
| Taiho Oncology, INC. | $67.39 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $66.57 | 2024-2025 | |
| Lilly USA, LLC | $59.43 | 2019-2024 | Jaypirca, Verzenio |
| Tersera Therapeutics LLC | $58.73 | 2019-2024 | Zoladex |
| Regeneron Healthcare Solutions, INC. | $53.29 | 2023-2024 | Libtayo |
| Servier Pharmaceuticals LLC | $52.52 | 2023-2024 | |
| Incyte Corporation | $50.81 | 2020-2025 | Jakafi, Monjuvi |
| Array Biopharma INC | $45.90 | 2025 | Braftovi, Lorbrena, Mektovi |
| Alexion Pharmaceuticals, INC. | $45.69 | 2023-2025 | Ultomiris |
| Coherus Oncology, INC. | $44.95 | 2023-2024 | |
| Adc Therapeutics America, INC. | $42.80 | 2023-2025 | |
| Glaxosmithkline, LLC. | $35.68 | 2024-2025 | Ojjaara |
| Novo Nordisk INC | $32.14 | 2020 | |
| Tesaro, INC. | $31.87 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $27.40 | 2019 | |
| Beigene USA, INC. | $27.31 | 2025 | Brukinsa |
| Stemline Therapeutics INC. | $27.25 | 2023 | Orserdu |
| Theratechnologies INC. | $24.83 | 2025 | Trogarzo, Egrifta |
| Geron Corporation | $23.93 | 2025 | Rytelo |
| Rigel Pharmaceuticals, INC. | $22.89 | 2024 | Rezlidhia, Tavalisse |
| Janssen Pharmaceuticals, INC | $20.97 | 2023 | Xarelto |
| Eisai INC. | $18.93 | 2019 | |
| Melinta Therapeutics, LLC | $17.90 | 2020 | |
| Ucb, INC. | $17.07 | 2025 | Bimzelx |
| La Jolla Pharmaceutical Company | $16.44 | 2023 | Xerava |
| Antares Pharma, INC. | $16.16 | 2020 | |
| Sobi, INC | $16.08 | 2025 | |
| Jazz Pharmaceuticals INC. | $15.57 | 2024 | |
| Abbvie INC. | $15.39 | 2024 | |
| Caris Mpi, INC. | $14.58 | 2025 | Mi Cancer Seek |
| Foundation Medicine, INC. | $13.05 | 2023 | Foundationone Liquid Cdx |
| Karyopharm Therapeutics INC. | $12.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Marte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.